Summary of Research
This is a summary of the original article ‘Safety and efficacy of bimekizumab in patients with psoriatic arthritis: 2-year results from two phase 3 studies’ (Fig. 1) [1].
[See PDF for image]
Fig. 1
Summary of Research
[See PDF for image]
Acknowledgements
Please see original article for full acknowledgements.
Medical Writing/Editorial Assistance
The authors acknowledge Orla Woodward, PhD, Costello Medical, London, UK for medical writing and editorial assistance based on the authors’ input and direction, and the Costello Medical Creative team for design support. Support for third-party writing assistance for this article was funded by UCB in accordance with Good Publication Practice (GPP 2022) guidelines (https://doi.org/10.7326/M22-1460).
Author Contributions
All authors of the original article reviewed and approved this summary of research.
Funding
These studies were sponsored by UCB. The journal’s Rapid Service Fee was funded by UCB.
Data Availability
Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.
Declarations
Conflict of Interest
Please see original article for full author disclosures. Yoshiya Tanaka and Laura C. Coates are Editorial Board members of Rheumatology and Therapy. They were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Philip J. Mease has also received research grants from Sana; consulting fees from Cullinan and GSK.
Ethical Approval
This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Please see the referenced article for ethics relating to the original study.
Reference
1. Mease, PJ; Merola, JF; Tanaka, Y et al. Safety and efficacy of bimekizumab in patients with psoriatic arthritis: 2-year results from two phase 3 studies. Rheumatol Ther; 2024; 11, pp. 1363-1382. [DOI: https://dx.doi.org/10.1007/s40744-024-00708-8] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/39215949][PubMedCentral: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11422409]
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
This Summary of Research summarises results from the BE OPTIMAL (NCT03895203) and BE COMPLETE (NCT03896581) studies and their open-label extension, BE VITAL (NCT04009499). These phase 3 studies looked at how well bimekizumab treatment worked in patients with psoriatic arthritis, and the safety of bimekizumab treatment, over the long term. Two patient groups were included in these studies: patients who had not previously been treated with biologic disease-modifying antirheumatic drugs (bDMARD-naïve; BE OPTIMAL) and patients who had a poor response or were intolerant to tumour necrosis factor (TNF) inhibitors (BE COMPLETE). These studies showed that the beneficial effects of bimekizumab treatment on patients’ symptoms reported at year 1 of treatment were sustained up to 2 years, regardless of whether patients were bDMARD-naïve or had previously had a poor response or intolerance to TNF inhibitors. Bimekizumab was well tolerated up to 2 years. The data from this study may help clinicians and patients when they are making shared decisions on treatment options for psoriatic arthritis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Providence-Swedish Medical Center and University of Washington, Department of Rheumatology, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657)
2 UT Southwestern Medical Center, Department of Dermatology and Department of Medicine, Division of Rheumatology, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121)
3 University of Occupational and Environmental Health, Japan, The First Department of Internal Medicine, Kitakyushu, Japan (GRID:grid.271052.3) (ISNI:0000 0004 0374 5913)
4 Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France (GRID:grid.7429.8) (ISNI:0000000121866389); AP-HP, Pitié-Salpêtrière Hospital, Rheumatology Department, Paris, France (GRID:grid.411439.a) (ISNI:0000 0001 2150 9058)
5 University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, UK (GRID:grid.8756.c) (ISNI:0000 0001 2193 314X)
6 University of Rochester Medical School, Allergy, Immunology & Rheumatology Division, Rochester, USA (GRID:grid.16416.34) (ISNI:0000 0004 1936 9174)
7 Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, The Netherlands (GRID:grid.16416.34); Zuyderland MC, Heerlen, The Netherlands (GRID:grid.16416.34)
8 The Jikei University School of Medicine, Department of Dermatology, Tokyo, Japan (GRID:grid.411898.d) (ISNI:0000 0001 0661 2073)
9 UCB, Slough, UK (GRID:grid.418727.f) (ISNI:0000 0004 5903 3819)
10 UCB Biosciences GmbH, Monheim am Rhein, Germany (GRID:grid.420204.0) (ISNI:0000 0004 0455 9792)
11 UCB, Morrisville, USA (GRID:grid.469275.b) (ISNI:0000 0004 0535 721X)
12 Oxford University Hospitals NHS Trust, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, University of Oxford and Oxford Biomedical Research Centre, Oxford, UK (GRID:grid.410556.3) (ISNI:0000 0001 0440 1440)